|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
15
|
|
pubmed:dateCreated |
2007-5-21
|
|
pubmed:abstractText |
Preoperative (neoadjuvant) chemotherapy for operable breast cancer downstages tumors initially not suitable for breast-conserving surgery. A pathologic complete response (pCR) to neoadjuvant chemotherapy may be a surrogate for longer overall survival, but this beneficial effect remains to be established. This phase III trial evaluated whether doubling the number of cycles of neoadjuvant treatment increased the pCR rate.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:ABCSG-14,
pubmed-author:GalidArikA,
pubmed-author:GnantMichaelM,
pubmed-author:GreilRichardR,
pubmed-author:HaidAntonA,
pubmed-author:JakeszRaimundR,
pubmed-author:KlugEduardE,
pubmed-author:KubistaErnstE,
pubmed-author:KwasnyWernerW,
pubmed-author:LangAloisA,
pubmed-author:Luschin-EbengreuthGeroG,
pubmed-author:MenzelChristianC,
pubmed-author:MlineritschBrigitteB,
pubmed-author:PöstlbergerSabineS,
pubmed-author:RudasMargarethaM,
pubmed-author:SamoniggHellmutH,
pubmed-author:SingerChristian FCF,
pubmed-author:StegerGünther GGG,
pubmed-author:TauschChristophC,
pubmed-author:WenzelCatharinaC
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2012-8
|
|
pubmed:meshHeading |
pubmed-meshheading:17513805-Adult,
pubmed-meshheading:17513805-Aged,
pubmed-meshheading:17513805-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17513805-Axilla,
pubmed-meshheading:17513805-Breast Neoplasms,
pubmed-meshheading:17513805-Carcinoma, Ductal, Breast,
pubmed-meshheading:17513805-Carcinoma, Lobular,
pubmed-meshheading:17513805-Chemotherapy, Adjuvant,
pubmed-meshheading:17513805-Epirubicin,
pubmed-meshheading:17513805-Female,
pubmed-meshheading:17513805-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:17513805-Humans,
pubmed-meshheading:17513805-Lymphatic Metastasis,
pubmed-meshheading:17513805-Middle Aged,
pubmed-meshheading:17513805-Neoadjuvant Therapy,
pubmed-meshheading:17513805-Neoplasm Staging,
pubmed-meshheading:17513805-Prospective Studies,
pubmed-meshheading:17513805-Taxoids
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14.
|
|
pubmed:affiliation |
Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria. guenther.steger@meduniwien.ac.at
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Multicenter Study
|
